Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subatomic Particles03:37

Subatomic Particles

94.1K
Dalton was only partially correct about the particles that make up matter. All matter is composed of atoms, and atoms are composed of three smaller subatomic particles: protons, neutrons, and electrons. These three particles account for the mass and the charge of an atom.
94.1K
Atomic Emission Spectroscopy: Interference01:30

Atomic Emission Spectroscopy: Interference

254
In atomic emission spectroscopy (AES), high-temperature atomizers excite a broad range of elements and molecules that generate complex emissions from sources such as oxides, hydroxides, and flame combustion products in the flame or plasma. Several strategies can be employed to minimize spectral interferences caused by overlapping emission lines or bands. These include increasing instrument resolution, choosing alternative emission lines, optimally placing the detector in low-background regions,...
254
Rocket Propulsion In Empty Space - II01:12

Rocket Propulsion In Empty Space - II

3.0K
The motion of a rocket is governed by the conservation of momentum principle. A rocket's momentum changes by the same amount (with the opposite sign) as the ejected gases. As time goes by, the rocket's mass (which includes the mass of the remaining fuel) continuously decreases, and its velocity increases. Therefore, the principle of conservation of momentum is used to explain the dynamics of a rocket's motion. The ideal rocket equation gives the change in velocity that a rocket...
3.0K
Rocket Propulsion in Empty Space - I01:13

Rocket Propulsion in Empty Space - I

3.3K
The driving force for the motion of any vehicle is friction, but in the case of rocket propulsion in space, the friction force is not present. The motion of a rocket changes its velocity (and hence its momentum) by ejecting burned fuel gases, thus causing it to accelerate in the direction opposite to the velocity of the ejected fuel. In this situation, the mass and velocity of the rocket constantly change along with the total mass of ejected gases. Due to conservation of momentum, the...
3.3K
Impulse01:13

Impulse

19.1K
According to Newton’s second law of motion, the rate of change of the momentum of an object is the net external force acting on it. The total change in momentum between two timepoints thus depends on both the external force acting on it and the time over which it acts. Describing this mathematically, the total change of an object’s motion is proportional to the force vector and the time over which it is applied. This product is called impulse.
Additionally, it can be shown that the...
19.1K
The Uncertainty Principle04:08

The Uncertainty Principle

23.6K
Werner Heisenberg considered the limits of how accurately one can measure properties of an electron or other microscopic particles. He determined that there is a fundamental limit to how accurately one can measure both a particle’s position and its momentum simultaneously. The more accurate the measurement of the momentum of a particle is known, the less accurate the position at that time is known and vice versa. This is what is now called the Heisenberg uncertainty principle. He...
23.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment.

Therapeutic advances in medical oncology·2026
Same author

Pan-cancer spatial atlas of tertiary lymphoid structures.

Science (New York, N.Y.)·2026
Same author

CXCL13-CXCR5 Signaling in CD8<sup>+</sup> T Cell Recruitment and Lymphoid Immune Organization in Clear Cell Renal Cell Carcinoma.

bioRxiv : the preprint server for biology·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Kidney Cancer Trends, Risk Factors, and Interventions in American Indian and Alaska Native Populations: The Kidney Cancer Association Scientific Statement.

Cancers·2026
Same author

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Cancer discovery·2026

Related Experiment Video

Updated: Aug 25, 2025

Visualization of Low-Level Gamma Radiation Sources Using a Low-Cost, High-Sensitivity, Omnidirectional Compton Camera
06:28

Visualization of Low-Level Gamma Radiation Sources Using a Low-Cost, High-Sensitivity, Omnidirectional Compton Camera

Published on: January 30, 2020

12.7K

Less is More? First Impressions From COSMIC-313.

Pavlos Msaouel1,2,3

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Cancer Investigation
|October 14, 2022
PubMed
Summary

The COSMIC-313 trial shows promising results for triplet therapy in advanced kidney cancer. Cabozantinib combined with nivolumab and ipilimumab offers a potential new first-line treatment option for metastatic clear cell renal cell carcinoma patients.

Keywords:
Renal cell carcinomacabozantinibclinical trialsipilimumabnivolumab

More Related Videos

Scattering And Absorption of Light in Planetary Regoliths
11:34

Scattering And Absorption of Light in Planetary Regoliths

Published on: July 1, 2019

10.4K
Cryo-EM and Single-Particle Analysis with Scipion
09:06

Cryo-EM and Single-Particle Analysis with Scipion

Published on: May 29, 2021

3.9K

Related Experiment Videos

Last Updated: Aug 25, 2025

Visualization of Low-Level Gamma Radiation Sources Using a Low-Cost, High-Sensitivity, Omnidirectional Compton Camera
06:28

Visualization of Low-Level Gamma Radiation Sources Using a Low-Cost, High-Sensitivity, Omnidirectional Compton Camera

Published on: January 30, 2020

12.7K
Scattering And Absorption of Light in Planetary Regoliths
11:34

Scattering And Absorption of Light in Planetary Regoliths

Published on: July 1, 2019

10.4K
Cryo-EM and Single-Particle Analysis with Scipion
09:06

Cryo-EM and Single-Particle Analysis with Scipion

Published on: May 29, 2021

3.9K

Area of Science:

  • Oncology
  • Clinical Trials
  • Renal Cell Carcinoma Research

Background:

  • Metastatic clear cell renal cell carcinoma (ccRCC) remains a significant challenge in oncology.
  • Current first-line treatments are evolving, with immunotherapy combinations showing efficacy.
  • The need for novel therapeutic strategies to improve patient outcomes in advanced ccRCC is critical.

Purpose of the Study:

  • To evaluate the efficacy and safety of a triplet combination therapy in first-line metastatic clear cell renal cell carcinoma.
  • To compare cabozantinib plus nivolumab and ipilimumab against nivolumab plus ipilimumab in advanced kidney cancer patients.
  • To present early findings from the COSMIC-313 phase 3 trial.

Main Methods:

  • Phase 3, randomized controlled trial design.
  • Inclusion of patients with metastatic clear cell renal cell carcinoma as first-line systemic therapy.
  • Comparison of triplet therapy (cabozantinib, nivolumab, ipilimumab) versus dual immunotherapy (nivolumab, ipilimumab).

Main Results:

  • The COSMIC-313 trial presents milestone results for renal cell carcinoma treatment.
  • Early findings suggest triplet combinations are emerging as potential first-line options.
  • Results were presented at the 2022 European Society of Medical Oncology Congress.

Conclusions:

  • The advent of triplet combinations, such as cabozantinib with nivolumab and ipilimumab, marks a significant development.
  • These findings signal a potential shift in first-line systemic therapy for metastatic clear cell renal cell carcinoma.
  • Further considerations and next steps are being explored based on these initial results.